Amalgamated Financial 주식 (NASDAQ: AMAL)

Amalgamated Financial (NASDAQ:AMAL) 주식

AMALGAMATED FINANCIAL CORP

Amalgamated Financial

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.

Amalgamated Financial Corp. - Common Stock

Amalgamated Financial Corp

HPE: 14% &#x7C; <a href="https://www.benzinga.com//node/46165707">Hewlett Packard Enterprise shares are trading higher after the company and Juniper Networks reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, clearing the way for the deal to close.</a>
&nbsp;
VERO: 59% &#x7C; <a href="https://www.benzinga.com//node/46153651">Venus Concept shares are trading higher after Madryn Asset Management increased its stake in the company to 85.5%.</a>
&nbsp;
WBUY: 64% &#x7C; <a href="https://www.benzinga.com//node/46165253">Webuy Global Partners With Coinbase Commerce To Launch Stablecoin Payment Option For Global Travel And E-Commerce Offerings</a>

Movers

Trading Ideas

VERO

WBUY

Market-Moving News for June 30th

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans
First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market
SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in preclinical studies.
Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD study enrolled 49 subjects.
The key findings include:
<ul>
<li>Excellent Safety Results: All adverse events (AEs) were mild, transient, and self-resolving. No drug-related AEs were observed in the blinded dataset, and no tolerability issues or safety signals were detected across multiple assessments (vital signs, ECGs, clinical laboratory tests, physical examinations, and visual analogue mood scales).</li>
<li>Predictable PK: Full dose-exposure profiles were successfully explored. Plasma analysis confirmed dose-dependent, linear absorption across the evaluated range.</li>
<li>Therapeutic Window: A wide safety margin was observed between estimated therapeutic plasma concentrations and the highest exposure levels achieved, supporting potential titration for maximum efficacy in future studies.</li>
</ul>

News

ARTL

Artelo Biosciences Announces Results From Its First-In-Human Study Evaluating ART26.12, Inhibitor Of FABP5; Says Results Affirm Safety And PK Profile Previously Observed In Preclinical Studies

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

Price Target

Analyst Ratings

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

Stifel analyst Brad Reback upgrades Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) from Hold to Buy and raises the price target from $180 to $250.

Upgrades

ORCL

Stifel Upgrades Oracle to Buy, Raises Price Target to $250

WIIM

JNPR

Juniper Networks shares are trading higher after the company and Hewlett Packard Enterprise reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, paving the way for the transaction to close.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/27/final-trades-kkr-co-lululemon-meta-and-rockwell-automation.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington, managing partner of Requisite Capital Management, said KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) is in big-time fundraising mode. The stock will go <a href="https://www.benzinga.com/quote/KKR">higher, she added</a>.
As per the recent news, Torrent Pharma, on Sunday, announced plans to acquire a controlling stake in JB Chemicals from KKR at INR 25,689 Cr valuation.
Brian Belski, chief investment strategist at BMO Capital Markets, said Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is quickly becoming a value stock again.
Lululemon Athletica reported a mixed shelf offering on June 26.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson, Capital Wealth Planning founder and CIO, named Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) as his final trade.
Supporting his view, Piper Sandler analyst Thomas Champion, on June 27, reiterated Meta Platforms with an Overweight rating and raised the price target from $650 to $808.
Stephanie Link, chief investment strategist and portfolio manager at Hightower, picked Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as her final trade.
Lending support to her choice, Keybanc analyst Ken Newman, on June 13, maintained Rockwell Automation with an Overweight rating and raised the price target from $345 to $360.
Price Action:
<ul class="wp-block-list">
<li>KKR shares gained 1.8% to close at $134.29 on Friday.</li>
<li>lululemon rose 1.5% to settle at $235.02 during the session.</li>
<li>Meta shares gained 1% to close at $733.63 on Friday.</li>
<li>Rockwell Automation shares gained 1.2% to settle at $329.95.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

LULU

Meta, KKR, Lululemon And An Industrial Stock On CNBC's 'Final Trades'

Hewlett Packard Enterprise shares are trading higher after the company and Juniper Networks reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, clearing the way for the deal to close.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30085723/GigaDevice.jpeg" alt="" class="wp-image-15068" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30085723/GigaDevice.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30085723/GigaDevice-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30085723/GigaDevice-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Shanghai-listed chip designer is applying for a second listing in Hong Kong, following a recent trend for Chinese companies to make such dual listings
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>GigaDevice has filed for a Hong Kong IPO, reporting its net profit surged in 2024 but is still well below the level from 2022</li>
<li>The chip maker's valuation is higher than its global peers, but its operations could be affected by U.S. export restrictions on chip design software</li>
</ul>
　A rush of Mainland China-listed companies onto the Hong Kong Stock Exchange, starting with home appliance maker Midea Group last September and culminating with the $4.5 billion listing for EV battery giant CATL, has sparked a goldrush among similar wannabes looking to hit up Hong Kong-based investors for cash. One of the latest to join that crowd is GigaDevice Semiconductor Inc. (603986.SH), which submitted its <a href="https://www1.hkexnews.hk/app/sehk/2025/107462/documents/sehk25061901285.pdf">listing application</a> earlier this month, and is also part of a growing tide of semiconductor firms with Hong Kong in its sights.
Founded in 2005 by Zhu Yiming and nurtured in the Beijing Tus Business Incubator, GigaDevice focuses on specialized memory and microcontroller unit (MCU) chips. It was restructured into a joint-stock company in December 2012 and brought in Hong Kong-based InfoGrid as a shareholder, before making its first listing in Shanghai in 2016. Currently, Zhu is the company's largest shareholder with a 6.89% stake, followed by Hong Kong InfoGrid, controlled by Shu Qingming, a former company director, with 1.97%.
<h4 class="wp-block-heading">Boom-bust cycles</h4>
Integrated circuits, as microchips are often called, have benefited in recent years from the rapid rise of AI and electric vehicles. As that happened, the global IC market grew from $356.2 billion in 2020 to $515.3 billion in 2024, averaging nearly 10% annual growth, according to third-party data in GigaDevice's listing document. As AI and other intelligent applications gain popularity and sophistication, the IC market is expected to reach $900.3 billion in 2029.
But while the broader IC sector continues to grow, certain segments are doing better than others. Notably, the memory chips that are GigaDevice's focus are a highly cyclical business, typically going through boom-bust cycles every four years over the last two decades.
Weakening demand from the consumer electronics market since 2022, coupled with an ongoing buildup in memory chip capacity in 2023 and a slowdown in global economic growth, have driven memory prices to rock bottom lately. Only rising demand from AI applications began to revive the market last year, kicking off a new growth phase as investors began to return to the sector.
GigaDevice's primary revenue drivers are specialized memory chips and MCUs, accounting for 70.6% and 23% of its revenue last year, respectively. They also contributed 79.7% and 23.6% of its 2024 gross profit. Specialized memory chips, including flash and niche DRAM, are used in areas such as consumer electronics, industrial applications, communications, and automotive electronics, responsible for data memory. MCUs, which integrate memory, timers, and other functional circuits onto a single chip, offer capabilities similar to central processing units (CPU) in personal computers.
Riding a growing wave of AI applications and recovering smartphone demand, GigaDevice's revenue rose 27.7% last year to 7.36 billion yuan ($1.03 billion). Revenue from specialized memory chips, which contributed 70% of the total, increased 27.4% to 5.20 billion yuan. That increase, together with a 7.3 percentage point year-on-year jump in that segment's gross profit margin to 40.3%, caused GigaDevice's net profit to surge nearly sevenfold to 1.10 billion yuan last year.
<h4 class="wp-block-heading">Declining chip prices</h4>
Despite last year's sharp profit rise, the figure is still 46.3% lower than the company's 2.05 billion yuan profit for 2022. What's more, the average selling prices of GigaDevice's two main businesses continued to decline. The average price of specialized memory chips dropped 31.8% from 2.14 yuan in 2022 to 1.46 yuan in 2024, while the price of MCUs over that time fell by nearly half from 8.22 yuan to 4.13 yuan.
It's also worth noting that GigaDevice's business is highly vulnerable to recent U.S. actions to stifle China's technology ambitions. The company relies heavily on imported electronic design automation (EDA) software in particular, since domestic alternatives remain relatively low quality. Global leaders in that space are U.S.-based Cadence, Synopsys, and Mentor Graphics, a U.S. subsidiary of Siemens, which hold 46%, 32%, and 14% of the global EDA market, respectively, or 92% collectively.
In discussing the risk factors it faces, GigaDevice disclosed that EDA software suppliers were recently told by the U.S. Department of Commerce's Bureau of Industry and Security (BIS) to stop supplying EDA software to China, which could negatively impact GigaDevice's design capabilities.
While GigaDevice mostly operates in the memory chip market, one of its biggest drawbacks is its inability to produce the high-bandwidth memory (HBM) that AI chip giant Nvidia (NVDA.US) requires most urgently. That is leaving it out in the cold in supplying to the rapid expansion and growth of data centers used to power AI applications. Instead, GigaDevice's memory chips are mostly used in consumer electronics and automotive electronics, which are highly susceptible to industry cycles.
The global memory chip market is currently led by South Korea's&nbsp;SK Hynix&nbsp;(000660.KS) and&nbsp;Samsung Electronics&nbsp;(005930.KS), which trade at forward price-to-earnings (P/E) ratios of approximately 6 times and 12 times, respectively. By comparison, GigaDevice's Shanghai-listed stock currently trades at a much higher forward P/E ratio of 50 times, which seems disproportionately high compared to its much larger and stronger global peers.
A Hong Kong listing at such a high valuation seems unlikely, at least not without some major breakthroughs by the company. Unless GigaDevice can break into the high-end memory chips its valuation is likely to come under pressure in its Hong Kong IPO.

Asia

IPOs

Opinion

GigaDevice Eyes Hong Kong IPO Amid Challenges

MRNA

Moderna shares are trading higher after the company reported results from its Phase 3 efficacy study evaluating its mRNA-1010 seasonal influenza vaccine in adults.

Zscaler shares are trading lower after the company announced plans to offer $1.5 billion in aggregate principal amount of convertible senior notes due 2028.

Rosenblatt analyst Barton Crockett maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and raises the price target from $18 to $39.

MGNI

Rosenblatt Maintains Buy on Magnite, Raises Price Target to $39

Cryptocurrency markets are trading flat on Monday morning, with the Fear and Greed Index at a neutral 52, according to data by CoinMarketCap.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,795.52</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,461.70</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$150.49</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.17</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1650</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001146</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume decreased by 7% and 11.5%, respectively. Daily active addresses for BTC and ETH were down by 10.5% and 2.4%, respectively.</li>
<li>Coinglass data shows 84,098 traders were liquidated in the past 24 hours for $208.35 million.</li>
<li>SoSoValue data shows net inflows of $501.27 million into spot Bitcoin ETFs on Friday, while spot Ethereum ETFs saw net outflows of $77.45 million.</li>
</ul>
Trader Notes: Crypto trader Jelle highlighted that Bitcoin is just hours away from securing a record-breaking monthly close. After taking out January's highs last month, BTC retested and held them this month, setting the stage for a potentially more bullish July.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">17 hours away from locking in another record-breaking monthly close. Broke the January highs last month &#8211; retested them this month, and pushed higher once more. July should be even better.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/UAsHi9Vt5Q">pic.twitter.com/UAsHi9Vt5Q</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1939578495375450549?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Posty <a href="https://x.com/PostyXBT/status/1939609091342504081">said</a> Bitcoin remains in a consolidation range, dubbed "summer chop season," between $98,000 and $110,000. A close below $98,000 would signal bearish structure, while a breakout above $110,000 would confirm entry into new price discovery territory.
Despite the sideways action, BTC just posted its second-highest weekly candle close ever. Posty says bears are ignoring the underlying bullish strength and may soon face the consequences.
Crypto trader Coinvo <a href="https://x.com/ByCoinvo/status/1939625458548502652">sees</a> Ethereum following a classic Wyckoff accumulation pattern. If the structure holds, ETH is likely gearing up for a major breakout and new highs in the near term.
Rose Premium Signals <a href="https://x.com/VipRoseTr/status/1939382108642029806">noted</a> XRP is consolidating in a bullish pennant just under a multi-year supply zone. With the SEC lawsuit finally resolved, sentiment is shifting. A confirmed breakout could trigger a run toward the $5 mark.
Crypto Rand <a href="https://x.com/crypto_rand/status/1939612905567125865">pointed</a> to Solana breaking above its long-term downtrend resistance. If SOL can now reclaim and hold the $161 level, it would confirm a full bullish reversal, opening the door to stronger momentum.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46149584/why-crypto-investors-are-receiving-internal-revenue-service-warning-letters">Why Crypto Investors Are Receiving Internal Revenue Service Warning Letters</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Start Monday Flat As Traders Hope For Bullish July

Webuy Global shares are trading higher after the company integrated Coinbase to accept stablecoin payments.

Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>), a leading provider of rugged mobile solutions, today issued an update regarding the Letter of Intent (LOI) for a proposed reverse takeover (RTO), as originally announced via press release dated <a href="https://api.newsfilecorp.com/redirect/A85WPsvkxG">June 25, 2025</a>. The RTO is with a private US-based company (the "Target") that is building out Nvidia-based High-Performance Computing (HPC) AI factories to support the hyper growth of cloud-based artificial intelligence (AI) workloads.
Under the LOI, upon completion, Sonim shareholders will receive equity ownership in the combined company. While this equity ownership is currently valued at $17.5 million, Sonim shareholders will benefit from any future value appreciation of the combined entity.

SONM

Sonim Technologies Issues Update On Proposed Reverse Takeover With Nvidia-Based High-Performance Computing AI Factories

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Expands Strategic Partnership With Xiaomi To Power Fully Intelligent Auto Insurance For YU7

<ul>
<li>BridgeBio has received a $300 million upfront payment, strengthening the Company's balance sheet, and supporting the launch of Attruby&#xAE; and ongoing late-stage pipeline programs</li>
<li>Transaction monetizes 60% of BridgeBio's European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45x</li>
<li>In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients:
<ul>
<li>In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placebo</li>
<li>A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30</li>
<li>A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30</li>
</ul>
</li>
<li>Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency and UK Medicines and Healthcare Products Regulatory Agency</li>
</ul>

BBIO

BridgeBio Sells Portion Of Royalties From BEYONTTRA Sales In Europe To Blue Owl Capital For $300M

ABEO

Abeona Therapeutics Added To Russell 2000 And Russell 3000 Indexes Following ZEVASKYN FDA Approval

FTI Consulting Appoints Christopher Allen To Lead Payments Modernization Efforts Within Financial Services Practice

<ul>
<li>In the Phase 2 MINDFuL trial of XPro in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro&#x2122; treatment over placebo was observed in cognitive, behavioral and biological endpoints.</li>
<li>Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients. The most common adverse events (AE) were injection site reactions.</li>
<li>Additional analyses will be presented at Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-31, 2025) and the Company will submit for Breakthrough Therapy designation with the FDA.</li>
</ul>

Biotech

Health Care

General

INMB

INmune Bio Says Phase 2 MINDFuL Trial Evaluating XPro In Early Alzheimer's With Biomarkers Of Inflammation Did Not Meet The Primary Cognitive Endpoint

PVLA

Palvella Therapeutics Added To Russell 3000 Index And Russell 2000 Index, Effective June 30, As Part Of 2025 Russell Indexes Reconstitution

Dividends

Press Releases

Amalgamated Financial Corp. Announces a 17% Quarterly Dividend Increase

Earnings

Amalgamated Financial Corp. Reports Fourth Quarter 2024 Financial Results: Solid Loan Growth; Net Interest Margin Rises to 3.59%

Amalgamated Financial Corp. Announces New $40 Million Share Repurchase Program

GS Power Partners Secures $22M in Financing with Amalgamated Bank

Amalgamated Bank Partners with Allectrify to Close First Adjustable-Rate C-PACE Transaction in Oklahoma County

Amalgamated Financial Corp. Announces First Quarter 2025 Earnings Conference Call

Amalgamated Financial Corp. Declares Regular Quarterly Dividend

Amalgamated Financial Corp. Reports First Quarter 2025 Financial Results; $446 Million Total Deposit Growth; Strong Margin at 3.55%

Financing

Amalgamated Bank Joins Nearly $1 Billion Aggregate Financing with Greenbacker's 674 MW Cider Solar Farm, Powering New York's Largest Solar Project to Date

Amalgamated Bank Advances Climate Leadership with C-PACE Financing for 205kW Solar Energy and Roofing Project in New Bedford

Comments

Amalgamated Financial

뉴스

파트너 / 기고자

벤징가 글로벌